JP2019531261A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531261A5
JP2019531261A5 JP2019503956A JP2019503956A JP2019531261A5 JP 2019531261 A5 JP2019531261 A5 JP 2019531261A5 JP 2019503956 A JP2019503956 A JP 2019503956A JP 2019503956 A JP2019503956 A JP 2019503956A JP 2019531261 A5 JP2019531261 A5 JP 2019531261A5
Authority
JP
Japan
Prior art keywords
compound
subject
level
biological sample
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019503956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531261A (ja
JP6987123B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/044151 external-priority patent/WO2018022866A1/en
Publication of JP2019531261A publication Critical patent/JP2019531261A/ja
Publication of JP2019531261A5 publication Critical patent/JP2019531261A5/ja
Application granted granted Critical
Publication of JP6987123B2 publication Critical patent/JP6987123B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019503956A 2016-07-28 2017-07-27 化合物、試薬およびその使用 Active JP6987123B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367839P 2016-07-28 2016-07-28
US62/367,839 2016-07-28
PCT/US2017/044151 WO2018022866A1 (en) 2016-07-28 2017-07-27 Diagnostic methods, therapeutic agents and uses thereof

Publications (3)

Publication Number Publication Date
JP2019531261A JP2019531261A (ja) 2019-10-31
JP2019531261A5 true JP2019531261A5 (cg-RX-API-DMAC10.html) 2020-09-03
JP6987123B2 JP6987123B2 (ja) 2021-12-22

Family

ID=59579921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503956A Active JP6987123B2 (ja) 2016-07-28 2017-07-27 化合物、試薬およびその使用

Country Status (8)

Country Link
US (1) US10865183B2 (cg-RX-API-DMAC10.html)
EP (1) EP3491004B1 (cg-RX-API-DMAC10.html)
JP (1) JP6987123B2 (cg-RX-API-DMAC10.html)
CN (1) CN109563127B (cg-RX-API-DMAC10.html)
AU (1) AU2017301949B2 (cg-RX-API-DMAC10.html)
CA (1) CA3032116A1 (cg-RX-API-DMAC10.html)
ES (1) ES2891088T3 (cg-RX-API-DMAC10.html)
WO (1) WO2018022866A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3410115A1 (en) * 2013-05-14 2018-12-05 Metabolon, Inc. Tryptophan as a biomarkers for kidney function and methods using the same
US11182920B2 (en) * 2018-04-26 2021-11-23 Jerry NAM Automated determination of muscle mass from images
TWI669506B (zh) * 2018-07-06 2019-08-21 國軍桃園總醫院 計算腎絲球過濾率之方法
WO2021126158A1 (en) * 2019-12-16 2021-06-24 Hill's Pet Nutrition, Inc. Methods, kits and compositions for diagnosing and treating renal disease
CN114026427B (zh) * 2020-05-19 2023-11-17 深圳市中医院 诊断肾病的标志物以及诊断方法
AU2020480829A1 (en) 2020-12-07 2023-07-20 Kimberly-Clark Worldwide, Inc. Methods and consumer products for detecting a metabolite
AU2022429891A1 (en) * 2021-12-27 2024-06-06 Société des Produits Nestlé S.A. Compositions and methods for diagnosing and treating chronic kidney disease
CN119355249A (zh) * 2024-09-20 2025-01-24 长沙都正生物科技股份有限公司 苯乙酰谷氨酰胺及其与氧化三甲胺联用作为糖尿病肾病诊断标志物
WO2026120352A1 (en) * 2024-12-03 2026-06-11 Societe Des Produits Nestle Sa Estimating glomerular filtration rates in felines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3410115A1 (en) * 2013-05-14 2018-12-05 Metabolon, Inc. Tryptophan as a biomarkers for kidney function and methods using the same
US10393749B2 (en) 2013-12-11 2019-08-27 Shiseido Company, Ltd. Marker for early diagnosis of kidney failure

Similar Documents

Publication Publication Date Title
JP2016520192A5 (cg-RX-API-DMAC10.html)
JP2020112568A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
AU2014265669B2 (en) Biomarkers related to kidney function and methods using the same
JP6321080B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
EA201290711A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
RU2009139295A (ru) Биомаркеры и биомаркерные признаки почечной сохранности, обладающие предсказательной силой, для использования в мониторинге состояния почек
JP2017078719A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2014505259A (ja) 慢性心不全における予後診断および診断の方法
BR112014006741A2 (pt) método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial
JP7109441B2 (ja) 神経変性疾患を判定するための診断補助方法
JP6186400B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
MX2020009705A (es) Metodos para la deteccion del riesgo de enfermedad renal cronica en un sujeto y metodo implementado por computadora.
ES2690486T3 (es) Biomarcador de enfermedad renal crónica
JP2018529931A5 (cg-RX-API-DMAC10.html)
EA201290056A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
WO2014140974A3 (en) System and method for determining risk of diabetes based on biochemical marker analysis
CY1119797T1 (el) Λακτοφερινη για χρηση στη διαγνωση και προγνωση της νοσου alzheimer
JP2016029379A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
Liu et al. Assessment of glomerular filtration rate in elderly patients with chronic kidney disease
JP2016532115A5 (cg-RX-API-DMAC10.html)
Gentilini et al. Validation of a human immunoturbidimetric assay to measure canine albumin in urine and cerebrospinal fluid
JP2015528562A5 (cg-RX-API-DMAC10.html)
Venetsanos et al. Glomerular filtration rate (GFR) during and after STEMI: a single-centre, methodological study comparing estimated and measured GFR
FI3543702T3 (fi) Menetelmiä koehenkilön kroonisen munuaissairauden riskin seulomiseksi ja tietokoneella toteutettu menetelmä
CN103189394B (zh) 利用透明质酸评价肾损伤的方法和组合物